CVS Health 2024: how Karen Lynch faced board pressure, restructured operations, closed 900 stores, and ended with David Joyner as CEO mid-year

The post-Aetna conglomerate structure

CVS Health acquired Aetna on November 28, 2018 for approximately $69 billion. The strategic logic was vertical integration: combine PBM (CVS Caremark), retail pharmacy (CVS Pharmacy), and health insurance (Aetna) into a single integrated healthcare company. The thesis was that vertical integration would produce member-experience improvements, cost-control benefits, and pricing power that pure-play competitors couldn't match.

Through 2019-2023, the integration produced mixed results:

• Revenue scale: CVS Health grew to over $300B annual revenue, making it one of the largest companies in the US.
• Integration friction: combining cultures across PBM, retail, and insurance proved more difficult than projected. Operational decisions had to balance competing segment interests.
• Aetna medical-loss-ratio pressure: as broader healthcare costs accelerated post-pandemic, Aetna's medical-loss ratio (the share of premium revenue paid as medical claims) increased substantially.
• PBM scrutiny: CVS Caremark, as one of three major PBMs (alongside Express Scripts/Cigna and OptumRx/UnitedHealth), faced increased regulatory and political scrutiny.
• Retail pharmacy pressure: front-of-store retail sales declined; prescription dispensing margins compressed.
• Healthcare services expansion: CVS Health invested in MinuteClinic primary-care expansion, Oak Street Health acquisition ($10.6B closed May 2023), Signify Health ($8B closed March 2023) for home-care services.

The 2024 deterioration and the Lynch transition

Through 2024 multiple pressures intensified:

• Q2 2024 earnings miss: CVS reported Aetna medical-loss ratio of 89.6% (well above 87% target). Stock fell 17% on the announcement.
• August 2024 announcement of 900 store closures: CVS announced it would close approximately 900 retail pharmacy locations over three years (10% of footprint). The closures reflected continued retail-pharmacy economic pressure.
• Glenview Capital activist position: investor Glenview took approximately $700M position through 2024 and publicly called for strategic alternatives including potential break-up of CVS-Aetna-Caremark structure.
• Q3 2024 earnings disappointment: continued Aetna medical-loss-ratio pressure (95.2% in Q3). Karen Lynch publicly acknowledged challenges.
• October 18, 2024 CEO transition announced: Karen Lynch departed; David Joyner (CVS Caremark president, longtime CVS executive) appointed CEO. The transition was clearly forced by accumulated operational and strategic pressures.
• David Joyner background: longtime CVS executive who had run CVS Caremark for years; deep operational knowledge of company but less strategic-visionary positioning than Lynch had.
• Initial Joyner strategic communications: emphasized operational execution and cost discipline; signaled continuation of existing strategy with operational refinement rather than dramatic strategic-direction reset.

The Aetna challenges and the medical-loss-ratio pressure

Aetna's medical-loss-ratio pressure has been the most-visible operational challenge:

• 2023 medical-loss ratio ~86.2%: in line with expectations.
• 2024 trajectory worsened: Q1 87.3%, Q2 89.6%, Q3 95.2% — substantially above target.
• Drivers: higher-than-expected medical costs across Medicare Advantage and individual exchange plans; specific Medicaid plans facing utilization above projections; pharmacy-cost growth from GLP-1 drugs (Ozempic, Wegovy, Mounjaro) substantial.
• Aetna structural position: ~25M+ members across commercial, Medicare Advantage, Medicaid, and individual exchanges. Medicare Advantage exposure is particularly significant.
• Industry-wide context: UnitedHealth (UnitedHealthcare), Humana, Elevance Health, others also reporting elevated medical-cost ratios. The pressure is sector-wide, not CVS-specific.
• Pricing-correction timing: insurance pricing operates with multi-year lags; 2024 pricing was set in 2023 based on lower cost projections. Pricing adjustments will take 2025-2026 to flow through. Aetna's operating-margin compression is likely to continue through 2025.

The retail pharmacy sector challenges

Beyond Aetna, the retail pharmacy segment has faced broader pressure:

• Retail pharmacy industry under pressure: Walgreens (also restructuring; ~1,200 stores closing), Rite Aid (Chapter 11 October 2023), Bartell Drugs (Walgreens-owned), various regional chains all face similar pressure.
• Prescription dispensing margin compression: PBM reimbursement rates (paid by CVS Caremark and other PBMs to pharmacies including CVS Pharmacy retail) have declined over years, compressing per-prescription margins.
• Front-of-store retail decline: walk-in retail purchasing (cosmetics, snacks, basics) has declined as consumers shifted to Amazon, Walmart, Target, and grocery.
• CVS 900-store closure plan: announced August 2024; staggered over three years; closures focused on overlapping locations and underperforming stores. Approximately 10% of total US footprint.
• Amazon Pharmacy growth: Amazon's prescription delivery service has grown, gaining share particularly among younger consumers.
• Walmart healthcare expansion (then retreat): Walmart had been expanding Walmart Health clinics; announced April 2024 it would close all Walmart Health clinics after failing to achieve profitability. The retreat reduced one CVS competitive threat but the broader pharmacy-sector economic pressure remains.

How RGM thinks about healthcare-conglomerate strategic execution

CVS Health's 2024 chapter is the worked example of healthcare-conglomerate strategic-execution challenges. The structural difficulty: combining PBM, retail pharmacy, and health insurance into single company produces theoretical synergies but operational complexity that's difficult to execute. UnitedHealth's similar conglomerate structure (UnitedHealthcare + OptumRx + Optum Health + Optum Insight) has operated more successfully because UNH has had longer integration runway and stronger operational discipline.

Our framework for clients in similar healthcare-conglomerate situations: vertical integration in healthcare requires sustained operational discipline that takes 5-10 years to develop. CVS-Aetna integration (now 6 years post-close) hasn't produced the projected synergies. The Glenview Capital break-up thesis (separate CVS-Caremark-Aetna components) has structural logic but would require complex separation with substantial transition costs. We tell clients in similar situations that healthcare-conglomerate strategy requires either patient long-term integration execution (UnitedHealth model) or honest acknowledgment that the integrated structure isn't producing value and separation should be considered. The David Joyner-era CVS will be judged on which path the company chooses.

Frequently asked questions

Related